Shahnawaz Mohammad , Anjali Kariyarath Valappil , Md. Rezaul Karim , Safia Iqbal , Deok Chun Yang , Changbao Chen , Li Ling , Dong Uk Yang
{"title":"Protective roles of genistein and icaritin in skin barrier integrity and hydration in an atopic dermatitis model","authors":"Shahnawaz Mohammad , Anjali Kariyarath Valappil , Md. Rezaul Karim , Safia Iqbal , Deok Chun Yang , Changbao Chen , Li Ling , Dong Uk Yang","doi":"10.1016/j.eujim.2025.102483","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Atopic dermatitis (AD) is a common chronic skin condition that primarily affects children and is characterized by impaired skin barrier function. Factors such as immune dysregulation and filaggrin deficiency contribute to barrier dysfunction. This study investigates the protective effects of genistein and icaritin in an AD-like model, focusing on their impact on skin barrier integrity, hydration, tight junction stability, and antimicrobial peptide production.</div></div><div><h3>Methods</h3><div>Human epidermal keratinocytes (HaCat cells) were cultured in Dulbecco’s modified Eagle medium with 10 % FBS and 1 % penicillin-streptomycin at 37 °C in 5 % CO<sub>2</sub> for 24 h. For the MTT assay, cells were plated at 1 × 10⁵ cells per well and treated with various concentrations of icaritin, genistein, their combinations, and dexamethasone. We established an AD-like inflammation model by treating the HaCat cells with TNF-α + IFN-γ (5 ng/ml), followed by extracting RNA and performing qRT-PCR using SYBR TOPreal, with GAPDH as the reference gene. The data are expressed as mean±<em>S</em>.D. (<em>n</em> = 3).</div></div><div><h3>Results</h3><div>Icaritin (6.25 and 12.5 μg/ml) and genistein (6.25 and 12.5 μg/ml) demonstrated no cytotoxic effects on HaCaT cells. Treatment significantly upregulated the expression of barrier-related genes, including filaggrin (<em>FLG</em>) with a fold change of 1.17 (genistein, 6.25 μg/ml, <em>p</em> < 0.01) and 1.16 (12.5 μg/ml, <em>p</em> < 0.05), <em>Claudin-1</em> (0.75 (icaritin, 12.5 µg/ml, <em>p</em> < 0.001), and <em>ZO-1</em> expression was significantly upregulated (1.79-fold) following combined treatment (<em>p</em> < 0.001). Furthermore, hyaluronic acid synthases (<em>HAS-1</em>, 1.66; <em>HAS-2</em>, 1.23) and <em>hBD3</em> (1.98 at combined treatment) were notably increased.</div></div><div><h3>Conclusion</h3><div>Genistein and icaritin significantly enhance skin barrier integrity and hydration in HaCaT cells, upregulating key proteins including filaggrin and aquaporin 3, indicating their therapeutic potential in AD management.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"76 ","pages":"Article 102483"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Integrative Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876382025000356","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Atopic dermatitis (AD) is a common chronic skin condition that primarily affects children and is characterized by impaired skin barrier function. Factors such as immune dysregulation and filaggrin deficiency contribute to barrier dysfunction. This study investigates the protective effects of genistein and icaritin in an AD-like model, focusing on their impact on skin barrier integrity, hydration, tight junction stability, and antimicrobial peptide production.
Methods
Human epidermal keratinocytes (HaCat cells) were cultured in Dulbecco’s modified Eagle medium with 10 % FBS and 1 % penicillin-streptomycin at 37 °C in 5 % CO2 for 24 h. For the MTT assay, cells were plated at 1 × 10⁵ cells per well and treated with various concentrations of icaritin, genistein, their combinations, and dexamethasone. We established an AD-like inflammation model by treating the HaCat cells with TNF-α + IFN-γ (5 ng/ml), followed by extracting RNA and performing qRT-PCR using SYBR TOPreal, with GAPDH as the reference gene. The data are expressed as mean±S.D. (n = 3).
Results
Icaritin (6.25 and 12.5 μg/ml) and genistein (6.25 and 12.5 μg/ml) demonstrated no cytotoxic effects on HaCaT cells. Treatment significantly upregulated the expression of barrier-related genes, including filaggrin (FLG) with a fold change of 1.17 (genistein, 6.25 μg/ml, p < 0.01) and 1.16 (12.5 μg/ml, p < 0.05), Claudin-1 (0.75 (icaritin, 12.5 µg/ml, p < 0.001), and ZO-1 expression was significantly upregulated (1.79-fold) following combined treatment (p < 0.001). Furthermore, hyaluronic acid synthases (HAS-1, 1.66; HAS-2, 1.23) and hBD3 (1.98 at combined treatment) were notably increased.
Conclusion
Genistein and icaritin significantly enhance skin barrier integrity and hydration in HaCaT cells, upregulating key proteins including filaggrin and aquaporin 3, indicating their therapeutic potential in AD management.
期刊介绍:
The European Journal of Integrative Medicine (EuJIM) considers manuscripts from a wide range of complementary and integrative health care disciplines, with a particular focus on whole systems approaches, public health, self management and traditional medical systems. The journal strives to connect conventional medicine and evidence based complementary medicine. We encourage submissions reporting research with relevance for integrative clinical practice and interprofessional education.
EuJIM aims to be of interest to both conventional and integrative audiences, including healthcare practitioners, researchers, health care organisations, educationalists, and all those who seek objective and critical information on integrative medicine. To achieve this aim EuJIM provides an innovative international and interdisciplinary platform linking researchers and clinicians.
The journal focuses primarily on original research articles including systematic reviews, randomized controlled trials, other clinical studies, qualitative, observational and epidemiological studies. In addition we welcome short reviews, opinion articles and contributions relating to health services and policy, health economics and psychology.